Australia markets closed

LLY Oct 2024 580.000 call

OPR - OPR Delayed price. Currency in USD
Add to watchlist
255.090.00 (0.00%)
As of 10:06AM EDT. Market open.
Full screen
Previous close255.09
Open255.09
Bid0.00
Ask0.00
Strike580.00
Expiry date2024-10-18
Day's range224.00 - 255.09
Contract rangeN/A
Volume1
Open interest2
  • Yahoo Finance Video

    Jobs data, Alphabet's new CFO, HPE earnings: Three things

    It's another busy day on Wall Street. Here are three of the top stories to watch in Wednesday's trading. The US added 152,000 private sector jobs in May, according to the latest ADP report. That's fewer than the 175,000 economists polled by Bloomberg were expecting. It's giving investors some hope that the Federal Reserve will cut rates sooner than some have been expecting. Alphabet (GOOGL, GOOG) announced Anat Ashkenazi, currently Executive Vice President and Chief Financial Officer at Eli Lilly (LLY), will be joining the company as its new CFO effective July 31. The tech giant announced last year that Ruth Porat would be stepping away from the role to become the company's President and Chief Investment Officer. Shares of Hewlett Packard Enterprise (HPE) are surging after reporting second quarter results that topped Street estimates and issuing better-than-expected Q3 and full-year guidance. For more expert insight and the latest market action, click here to watch this full episode of Morning Brief. This post was written by Stephanie Mikulich.

  • Reuters

    Alphabet names Lilly veteran Anat Ashkenazi as finance chief

    Ashkenazi will succeed Ruth Porat, the long-time Alphabet CFO whose transition to the role of investment chief was unveiled in July 2023 after years of strong growth at the company. The latest executive change comes at a crucial time for Alphabet.

  • PR Newswire

    Lilly announces departure of Anat Ashkenazi, chief financial officer

    Eli Lilly and Company (NYSE: LLY) announced today that Anat Ashkenazi has resigned as chief financial officer to pursue a career opportunity outside of the pharmaceutical industry.